Bernstein raised the firm’s price target on Vertex Pharmaceuticals to $363 from $344 and keeps an Outperform rating on the shares. The firm notes Vertex reported solid first-quarter results Monday night, beating consensus by 2% on revenue and 1% on adjusted EPS. While management left guidance unchanged, the Q1 performance makes a full-year guidance beat look likely in Bernstein’s view.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on VRTX:
- Vertex Pharmaceuticals price target raised to $315 from $299 at RBC Capital
- Vertex Pharmaceuticals price target raised to $456 from $341 at Truist
- Vertex Pharmaceuticals price target raised to $350 from $330 at TD Cowen
- Vertex Pharmaceuticals price target raised to $340 from $300 at Stifel
- Vertex Pharmaceuticals price target raised to $385 from $339 at Guggenheim
